by Michela Kane May 25, 2021 .
DURHAM – Smartwatches and other wearable devices may be used to sense illness, dehydration and even changes to the red blood cell count, according to biomedical engineers and genomics researchers at Duke University and the Stanford University School of Medicine.
The researchers say that, with the help of machine learning, wearable device data on heart rate, body temperature and daily activities may be used to predict health measurements that are typically observed during a clinical blood test. The study appears in Nature Medicine on May 24, 2021.
During a doctor’s office visit, a medical worker usually measures a patient’s vital signs, including their height, weight, temperature and blood pressure. Although this information is filed away in a person’s long-term health record, it isn’t usually used to create a diagnosis. Instead, physicians will order a clinical lab, which tests a patient’s urine or blood, to gather specific biological
E-Mail
Credit: Michaela Kane, Duke University
DURHAM, N.C. Smartwatches and other wearable devices may be used to sense illness, dehydration and even changes to the red blood cell count, according to biomedical engineers and genomics researchers at Duke University and the Stanford University School of Medicine.
The researchers say that, with the help of machine learning, wearable device data on heart rate, body temperature and daily activities may be used to predict health measurements that are typically observed during a clinical blood test. The study appears in
Nature Medicine on May 24, 2021.
During a doctor s office visit, a medical worker usually measures a patient s vital signs, including their height, weight, temperature and blood pressure. Although this information is filed away in a person s long-term health record, it isn t usually used to create a diagnosis. Instead, physicians will order a clinical lab, which tests a patient s urine or blood, to gather specific
Share this article
NEW YORK, May 6, 2021 /PRNewswire/
Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced financial results for the first quarter ended March 31, 2021 and highlighted recent activity. Our clinical program activities have continued unabated, with significant progress having recently been achieved for our lead asset, selective oral DHODH inhibitor, IMU-838, stated Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic. Last month, we announced key interim data from our phase 2 EMPhASIS Cohort 2 sub-trial of IMU-838 in patients with relapsing-remitting multiple sclerosis (RRMS), confirming 30 mg as the most appropriate dose for our envisaged phase 3 program. We will now move directly to the filing of an Investigational New Drug (IND) application in the United States and are currently working
Immunic Sets Optimal Dose of Oral IMU-838 for Phase 3 Trials in RRMS 4.8 (5)
Interim data from a Phase 2 trial of Immunic Therapeutics’ investigational oral therapy IMU-838 (vidofludimus calcium) in relapsing-remitting multiple sclerosis (RRMS) patients has established a once-daily, 30 mg dose as the most appropriate for future Phase 3 trials.
The company is now in discussions with regulatory authorities, including those in the U.S. and Europe, regarding pivotal Phase 3 testing expected to start later this year.
At the request of the U.S. Food and Drug Administration (FDA), Immunic will directly submit an investigational new drug (IND) application for the right to open a Phase 3 trial, instead of waiting for an end-of-Phase 2 meeting, it reported in a press release.
EV startups like Rivian and Lucid are joining the fight.
The years-long battle between franchised automotive dealerships and their powerful lobbyists against Tesla and newer electric vehicle startups like Rivian and Lucid is back in the news as 11 states are now considering legalizing direct sales. The only way to buy a new Tesla Model S or Rivian R1T, to name just two examples, is directly from the company instead of a franchised dealership.
Dealerships argue that customers benefit from privately owned dealers for a number of reasons, among them pricing competition, warranty repairs, and helping local economies. Electric vehicle brands say consumers receive the same necessary basic services and transparent pricing. Equally important, things like over-the-air updates and other software-related services that EVs require can be done more efficiently in a direct manufacturer-customer relationship.